Track market-moving stories before they get noisy

Golden Cross Alert: 3 Stocks With Major Upside PotentialWAVE Life Sciences NASDAQ: WVE outlined progress across its obesity-focused siRNA program and RNA editing pipeline during a Chardan discussion, with President and CEO Paul Bolno emphasizing the company’s chemistry platform, upcoming clinical studies and regulatory alignment for its alpha-1 antitrypsin deficiency program.

Bolno said the company entered the year with two principal objectives: generating Phase I data for WVE-007, an INHBE-targeting treatment being developed for obesity and cardiometabolic disease, and advancing what he described as the first RNA editing medicine to enter clinical testing for alpha-1 antitrypsin deficiency, or AATD.

Get WAVE Life Sciences alerts:

WVE-007 Data Highlight Body Composition Wave Life Sciences Rockets 70% on Historic RNA Editing SuccessAccording to Bolno, WVE-007 produced reductions in fat while preserving lean muscle mass in a Phase I healthy-volunteer study. He said the findings supported the potential for once-yearly dosing and showed a safety and tolerability profile that could support further development.

The company reported that a single dose resulted in nearly a 15% reduction in visceral fat, along with reductions in subcutaneous fat, a 3.3% reduction in waist circumference and a 1% change in body weight. Bolno stressed that the study enrolled healthy volunteers without comorbidities, a population he said generally has substantially less visceral and subcutaneous fat than patients in conventional obesity trials.

Sarepta Therapeutics Inc.: Why it's a rising gene therapy star“We did not just see a strong reduction in visceral fat,” Bolno said. “We saw a strong reduction in subcutaneous fat, which is what ultimately drives weight loss.”

He contrasted the results with other INHBE programs, saying Wave’s preclinical and clinical findings differentiated the company’s construct through deeper and more durable target suppression. Bolno attributed that potential differentiation to the company’s oligonucleotide chemistry and its ability to improve loading into the AGO2 component of the RNA-induced silencing complex, or RISC.

Bolno said Wave’s chemistry work produced nearly a 15-fold improvement in AGO2 loading in research described in a paper published several years ago. In the company’s view, that improvement may support potent knockdown and annual administration.

Phase II-A Studies to Assess Obesity and Cardiometabolic Outcomes Wave has begun dosing patients in its INLIGHT Phase II-A monotherapy study of WVE-007. The trial includes patients with body mass indexes ranging from 35 to 50 and permits participants with diabetes and other comorbidities, Bolno said.

The study includes two dose groups and separate diabetic and non-diabetic cohorts. In addition to measuring body weight and body composition, Wave plans to assess liver fat through MRI-PDFF, insulin sensitivity and lipid profiles. Bolno said the design could help the company evaluate potential applications beyond obesity, including metabolic dysfunction-associated steatohepatitis, or MASH, and diabetes.

Wave has also initiated a combination study of WVE-007 with tirzepatide. Bolno said the company sees potential use cases for the therapy as monotherapy in people with sarcopenic obesity, in combination with incretin therapies, and as a maintenance option following incretin treatment.

The company has not committed to a data-release date for the Phase II-A programs. Bolno said Wave may decide to unblind data at either three or six months, noting that the longer interval could provide a clearer view of weight change after lean mass stabilizes and fat reduction continues.

Alpha-1 Antitrypsin Program Moves Toward Registrational Study Bolno also discussed Wave’s RNA editing program for AATD, a genetic condition associated with lung and liver disease. He said early clinical data showed consistent editing across patients, with conversion of the disease-associated Z form to the normal M form of alpha-1 antitrypsin. The company also reported that treatment was safe and well tolerated in the data discussed.

Wave recently aligned with the FDA on what Bolno characterized as an innovative trial design that could shorten the path to approval. The company plans a two-year clinical trial intended to support registration, with a potential interim analysis at one year that could support accelerated approval.

Bolno said the company has observed acute-phase responses in more than one patient, including protein production above 20 micromolar during an inflammatory event in one case. He said the observations support the premise that RNA editing could enable patients to produce functional protein when it is needed during periods of inflammation.

While declining to disclose specific FDA discussions around thresholds for total alpha-1 antitrypsin or M-form protein, Bolno said Wave believes achieving an MZ-like phenotype could be an important component of an approval path.

Looking ahead, Bolno said Wave plans to discuss next-generation chemistry at its November research day, including bifunctional and multifunctional oligonucleotides. The company also expects to provide further information on its PNPLA3 RNA editing program, which targets liver-related diseases in patients homozygous for PNPLA3 variants.

About WAVE Life Sciences (NASDAQ:WVE)WAVE Life Sciences Ltd. NASDAQ: WVE is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in WAVE Life Sciences Right Now?Before you consider WAVE Life Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list.

While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

 | Source: Wave Life Sciences USA, Inc.

CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced it will host a virtual Research Day on Wednesday, November 4, 2026 at 9:30 a.m. ET.

During the event, Wave will share new data highlighting its differentiated RNA medicines platform, including its best-in-class chemistry, hepatic and extra-hepatic capabilities, and RNAi, RNA editing, and bifunctional modalities. The event will also feature perspectives on PNPLA3 I148M liver disease and the opportunity for an RNA editing correction approach from Arun J. Sanyal, MD, FAASLD, a leading hepatologist. Dr. Sanyal is a Z Reno Vlahcevic Professor of Medicine and Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University (VCU) School of Medicine.

Research Day Webcast
A webcast of the event can be accessed by visiting “Investor Events” on the investor relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the event can join the audio-conferencing link available here. Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
[email protected]

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
[email protected]

WAVE Life Sciences Ltd. (NASDAQ:WVE – Get Free Report)’s share price reached a new 52-week low during trading on Monday. The company traded as low as $3.37 and last traded at $3.3850, with a volume of 317,423 shares traded. The stock had previously closed at $3.46.

Analysts Set New Price Targets
WVE has been the topic of a number of research reports. Citigroup decreased their price target on shares of WAVE Life Sciences from $24.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Zacks Research downgraded shares of WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Mizuho lowered their price target on shares of WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th. UBS Group set a $13.00 price target on shares of WAVE Life Sciences in a research report on Monday, August 3rd. Finally, Wedbush set a $13.00 price objective on shares of WAVE Life Sciences in a research note on Friday, October 2nd. Fifteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, WAVE Life Sciences has an average rating of “Moderate Buy” and an average target price of $21.65.

Check Out Our Latest Stock Analysis on WAVE Life Sciences

WAVE Life Sciences Stock Performance
The firm’s fifty day simple moving average is $4.72 and its 200 day simple moving average is $5.91. The stock has a market capitalization of $661.10 million, a P/E ratio of -3.08 and a beta of -1.43.
WAVE Life Sciences (NASDAQ:WVE – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). The firm had revenue of $2.27 million for the quarter, compared to the consensus estimate of $7.45 million. WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%. Analysts anticipate that WAVE Life Sciences Ltd. will post -1.12 earnings per share for the current fiscal year.

Insider Activity at WAVE Life Sciences
In other WAVE Life Sciences news, Director Heidi L. Wagner sold 7,000 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total transaction of $42,070.00. Following the completion of the sale, the director directly owned 44,930 shares in the company, valued at $270,029.30. This represents a 13.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Adrian Rawcliffe sold 12,700 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total value of $67,183.00. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 23,564 shares of company stock valued at $132,476. Company insiders own 24.30% of the company’s stock.

Hedge Funds Weigh In On WAVE Life Sciences
Hedge funds and other institutional investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd bought a new position in shares of WAVE Life Sciences in the fourth quarter worth about $176,000. AlphaGrep UK Ltd bought a new stake in shares of WAVE Life Sciences during the 2nd quarter valued at approximately $78,000. First Trust Advisors LP grew its holdings in shares of WAVE Life Sciences by 15.7% during the 1st quarter. First Trust Advisors LP now owns 13,518 shares of the company’s stock valued at $98,000 after purchasing an additional 1,830 shares during the last quarter. Chicago Partners Investment Group LLC bought a new stake in shares of WAVE Life Sciences during the 1st quarter valued at approximately $124,000. Finally, Gabelli Funds LLC acquired a new position in WAVE Life Sciences during the 1st quarter worth approximately $127,000. Institutional investors own 89.73% of the company’s stock.

WAVE Life Sciences Company Profile
(Get Free Report)

WAVE Life Sciences Ltd. is a clinical-stage biotechnology company developing RNA medicines for genetic and other serious diseases. The company uses its proprietary oligonucleotide and RNA-editing technologies to target disease-causing genetic instructions, with the goal of selectively correcting, reducing, or modifying RNA activity.

Its development programs have included investigational therapies for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease.

Recommended Stories

Five stocks we like better than WAVE Life Sciences
China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
3 REITs That May Win in a Higher Interest Rate Environment
Broadcom’s Anthropic Bet Gets Bigger as $60 Billion Financing Raises the Stakes
Insider Buying Signals Opportunity in H.B. Fuller, FocalTherics, Cardinal

Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE – Get Free Report) rose 9.3% on Thursday. The company traded as high as $4.02 and last traded at $4.0440. 544,448 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 3,764,334 shares. The stock had previously closed at $3.70.

Analyst Upgrades and Downgrades A number of equities research analysts recently issued reports on the stock. Mizuho decreased their price target on shares of WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 4th. LADENBURG THALM/SH SH assumed coverage on shares of WAVE Life Sciences in a research note on Thursday. They issued a “buy” rating and a $10.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of WAVE Life Sciences in a report on Wednesday, September 23rd. They issued a “neutral” rating on the stock. Citigroup decreased their target price on shares of WAVE Life Sciences from $24.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of WAVE Life Sciences in a report on Friday, July 17th. Fifteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.65.

Read Our Latest Stock Report on WAVE Life Sciences

WAVE Life Sciences Price Performance The company has a market capitalization of $744.84 million, a P/E ratio of -3.47 and a beta of -1.42. The business has a 50-day moving average of $4.94 and a 200-day moving average of $6.25. WAVE Life Sciences (NASDAQ:WVE – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). WAVE Life Sciences had a negative net margin of 309.73% and a negative return on equity of 50.36%. The firm had revenue of $2.27 million for the quarter, compared to the consensus estimate of $7.45 million. Sell-side analysts predict that WAVE Life Sciences Ltd. will post -1.12 EPS for the current fiscal year.

Insider Activity In related news, Director Adrian Rawcliffe sold 12,700 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total transaction of $67,183.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Heidi Wagner sold 7,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total transaction of $42,070.00. Following the completion of the sale, the director directly owned 44,930 shares in the company, valued at $270,029.30. This trade represents a 13.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 23,564 shares of company stock worth $132,476 over the last quarter. 24.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows A number of hedge funds have recently modified their holdings of the business. AlphaCentric Advisors LLC boosted its holdings in WAVE Life Sciences by 5.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 29,175 shares of the company’s stock valued at $212,000 after acquiring an additional 1,585 shares during the period. First Trust Advisors LP increased its stake in WAVE Life Sciences by 15.7% in the first quarter. First Trust Advisors LP now owns 13,518 shares of the company’s stock worth $98,000 after purchasing an additional 1,830 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of WAVE Life Sciences during the fourth quarter worth $82,000. Arizona State Retirement System lifted its position in shares of WAVE Life Sciences by 17.1% during the second quarter. Arizona State Retirement System now owns 35,826 shares of the company’s stock worth $208,000 after purchasing an additional 5,228 shares during the last quarter. Finally, Quantinno Capital Management LP boosted its stake in shares of WAVE Life Sciences by 23.0% during the first quarter. Quantinno Capital Management LP now owns 47,885 shares of the company’s stock valued at $347,000 after purchasing an additional 8,960 shares during the period. Institutional investors own 89.73% of the company’s stock.

(Get Free Report)

WAVE Life Sciences Ltd. is a clinical-stage biotechnology company developing RNA medicines for genetic and other serious diseases. The company uses its proprietary oligonucleotide and RNA-editing technologies to target disease-causing genetic instructions, with the goal of selectively correcting, reducing, or modifying RNA activity.

Its development programs have included investigational therapies for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease.

See Also Five stocks we like better than WAVE Life Sciences AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved Time to Nibble on MCD Stock After it Enters Oversold Territory? McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 | Source: Wave Life Sciences USA, Inc.

Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers

WVE-006 (RNA editing) has potential to offer the AATD community a new standard-of-care treatment to protect the liver and lung with a safe and convenient therapy

CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced alignment with the U.S. Food and Drug Administration (FDA) on key aspects of its planned registrational pathway for WVE-006, an investigational GalNAc-RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency (AATD). Following the company’s FDA meeting, planning is underway for a two-year registrational trial to support potential full approval, with a one-year interim analysis to support potential accelerated approval based on AATD biomarkers. Additionally, the FDA supports the use of Wave’s current LC-MS assay to measure M-AAT (wild-type) and Z-AAT (mutant) protein for the WVE-006 registrational program.

“A registrational trial design that offers an efficient path to full approval, without the need for a separate confirmatory trial, is advantageous as we work to bring WVE-006 to the ~200,000 individuals living with Pi*ZZ AATD in the U.S. and Europe. Our discussions with key opinion leaders underscore the high unmet need and burden of the current standard of care, IV augmentation therapy, which may leave patients with depleted AAT levels during lung exacerbations, and does not address the risk of liver disease. WVE-006 avoids the irreversible bystander edits, indels and other off-target edits associated with DNA base editing. With the potential to address both lung and liver AATD with infrequent subcutaneous dosing and a favorable safety profile, we believe WVE-006 could meaningfully improve patients’ quality of life and offer a comprehensive treatment approach,” said Christopher Wright, MD, PhD, Chief Medical Officer at Wave Life Sciences.

WVE-006 is being evaluated in the ongoing Phase 1b/2a RestorAATion-2 open-label clinical trial in individuals with AATD who have the homozygous Pi*ZZ mutation, and Wave is on track to share data from the 600 mg (monthly) multidose cohort in the fourth quarter of 2026. WVE-006 continues to be generally safe and well tolerated with no liver toxicities.

About WVE-006
WVE-006 is a GalNAc-conjugated, subcutaneously delivered, A-to-I RNA editing oligonucleotide (AIMer) that was developed with Wave’s best-in-class oligonucleotide chemistry platform. By correcting the single RNA base mutation associated with the Pi*ZZ genotype, WVE-006 is designed to deliver a comprehensive treatment approach for AATD by producing healthy, wild-type M-AAT, decreasing unhealthy, mutant Z-AAT aggregates in liver, and dynamically increasing AAT, a protein responsible for protecting lungs against ongoing damage.

About Alpha-1 Antitrypsin Deficiency (AATD)
AATD can manifest as both lung and liver disease. It is a rare, inherited genetic disorder caused by a G-to-A point mutation in the SERPINA1 gene, referred to as the Z allele. Approximately 200,000 people in the U.S. and Europe are homozygous for the Z allele. In healthy individuals, wild-type, M-AAT protects the lung from proteolytic and inflammatory damage, particularly during exacerbations. In AATD, instead of wild-type, functional M-AAT traveling through the bloodstream to the lungs, mutant Z-AAT protein tends to get trapped in the liver and causes a lack of functional AAT in the lungs. Further, Pi*ZZ individuals have a reduced capacity to produce incremental AAT protein during an acute phase response. Together, these effects can lead to progressive lung disease, including chronic obstructive pulmonary disease (COPD) and early-onset emphysema, as well as liver disease, including fibrosis, cirrhosis, and hepatocellular carcinoma.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our plans for an efficient registrational trial; our understanding of the anticipated therapeutic benefits of WVE-006 as a therapy for AATD and the potential to address both lung and liver manifestations of the disease; WVE-006’s advantages in avoiding irreversible bystander edits, indels and other off-target edits associated with DNA base editing; our estimates of the AATD patient population that may benefit from WVE-006; our understanding of the dose levels and dosing frequency for WVE-006; our plans and estimated timing to share additional data from the RestorAATion-2 trial; our understanding of the safety profile of WVE-006. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
[email protected]

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
[email protected]

 | Source: Wave Life Sciences USA, Inc.

WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave’s INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 alone 

Maintenance clinical trial evaluating WVE-007’s ability to curtail weight regain after incretin cessation on track to initiate 2H 2026

CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the initiation of its Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA, in combination with tirzepatide in adults living with obesity.

“This combination trial of WVE-007 with weekly tirzepatide marks an important milestone in our development plan to advance WVE-007 across three distinct obesity treatment settings: monotherapy, combination therapy, and as a post-incretin maintenance therapy to prevent weight recurrence,” said Christopher Wright, MD, PhD, Chief Medical Officer at Wave Life Sciences. “Our preclinical data, as well as emerging clinical data in the field, support the potential for enhanced fat loss and preservation of muscle with WVE-007 as compared to incretins alone. The consequence of muscle loss is particularly important since beyond strength, skeletal muscle also plays an important role in both metabolism and weight maintenance. In our clinical data to date, we have demonstrated a differentiated profile for WVE-007, with potential for best-in-class INHBE silencing, favorable safety and tolerability, and once- or twice-yearly dosing.”

The INLIGHT™ clinical program is evaluating WVE-007 as a monotherapy and in combination with tirzepatide as a treatment for obesity and other cardiometabolic indications, including MASH. The placebo-controlled (3:1) Phase 2a combination trial will evaluate 240 mg and 400 mg doses of WVE-007 in combination with weekly tirzepatide in individuals living with obesity (BMI 35-50 kg/m2) and type 2 diabetes. The INLIGHT™ clinical program also includes an ongoing Phase 2a monotherapy trial, which includes multiple assessments over a 12-month period, and these results will inform further development of WVE-007 in obesity, as well as MASH, type 2 diabetes, and cardiovascular disease.

Wave also remains on track to initiate a clinical trial of WVE-007 as a maintenance therapy to preserve weight loss following discontinuation of incretin treatment in the second half of 2026.

Wave previously presented preclinical data at ObesityWeek® 2025 demonstrating that WVE-007 has potential for use synergistically with GLP-1s as well as to curtail weight regain after the cessation of treatment with GLP-1.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following, among others: the anticipated initiation, site activation, patient recruitment, patient enrollment, dosing, generation and reporting of data and/or completion of our INLIGHT clinical trial and the timing and announcement of such events; our expectations to initiate new clinical trials evaluating WVE-007 for post-incretin maintenance, and the expected results and timing thereof; the potential of WVE-007’s mechanism (INHBE GalNAc-siRNA) as a meaningful and differentiated therapeutic approach for obesity as well as the potential to develop WVE-007 for other indications, including MASH, type 2 diabetes, and cardiovascular disease; the future performance and results of WVE-007 in the Phase 2a portions of our INLIGHT clinical trial, including our expectations that there will be even greater improvements in body composition in individuals with higher BMI, visceral fat and body fat at baseline; the potential benefits of our toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), compared to others; the benefits of RNA medicines generally; and the potential for certain of our programs to be best-in-class. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual results to differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
[email protected]

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
[email protected]

 | Source: Wave Life Sciences USA, Inc.

Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer

CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Monika Vnuk, MD, as Chief Business Officer. Dr. Vnuk will join Wave’s executive team and lead business development, corporate development, and alliance management.

“We are thrilled to welcome Dr. Vnuk to Wave in a newly created leadership role as we continue to advance our pipeline to the next stages of development. Monika’s breadth of experience, including leading global business development teams and strategic asset financing, will be meaningful as we continue to expand the potential of our differentiated RNA medicines platform and support the next phase of Wave’s growth,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences.

“Wave has built a highly versatile and differentiated RNA medicines platform with multiple therapeutic modalities translating in the clinic. I am energized to join the company at such an exciting moment, as its science and pipeline programs create broad opportunity to advance value-creating transactions with the ultimate aim of expanding Wave’s positive impact on patients. I look forward to partnering with the Wave team to help drive the company’s growth and realize the full potential of its platform and pipeline,” said Monika Vnuk, MD, Chief Business Officer of Wave Life Sciences.

Prior to joining Wave, Dr. Vnuk served as Senior Vice President, Global Head of Partnering and Business Development for Sanofi, where she led global licensing, equity investments, and alliances. Prior to Sanofi, she was Managing Director at Blackstone Life Sciences, a private life sciences investing platform, where she was focused on late-stage product financing transactions. Dr. Vnuk spent more than a decade at Pfizer in senior business development roles, including Vice President, R&D Business Development, where she led the negotiation of the successful partnership with BioNTech directed at the global co-development and distribution of COVID-19 vaccines. Before Pfizer, she worked in investment banking at Bank of America and the life sciences venture capital firm Oxford Bioscience Partners. Dr. Vnuk earned an M.D. from Boston University School of Medicine and a B.A. in Mathematics and Philosophy from Boston University.

In connection with Dr. Vnuk joining Wave, she received a stock option to purchase 375,000 shares of common stock of Wave. The equity grant was approved by Wave’s Compensation Committee and granted to Dr. Vnuk on September 21, 2026, outside of the Wave Life Sciences, Inc. Amended and Restated 2021 Equity Incentive Plan, as an inducement material to Dr. Vnuk’s commencing employment with Wave, in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option has an exercise price of $4.25 per share, the closing price on the grant date, and vests over four years with 25% vesting on September 21, 2027, and the remainder vesting in equal quarterly installments over the following three years.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Dr. Vnuk’s leadership and global experience leading business development teams and strategic asset financing, strategic partnerships, licensing, equity investments and alliances; beliefs that Dr. Vnuk’s experience will benefit the next phase of Wave’s growth; beliefs that Wave’s portfolio of RNA medicines is differentiated, best-in-class and potentially transformative; the broad potential of Wave’s RNA medicines pipeline and oligonucleotide chemistry and any benefits that may be derived from them. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
[email protected]

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
[email protected]

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.

August 10, 2026 08:30 ET  | Source: Wave Life Sciences USA, Inc.

CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), today announced the completion of the redomiciliation process to change the parent company of the Wave group of companies from a Singapore company to a Delaware corporation by way of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Redomiciliation”).

The Redomiciliation was completed after the close of trading on Friday, August 7, 2026 (Eastern Time), at which time all issued ordinary shares of Wave Life Sciences Ltd. were exchanged on a one-for-one basis for newly issued shares of common stock of Wave Life Sciences, Inc., a Delaware corporation. Wave’s equity will continue to trade under the trading symbol of “WVE” and its newly issued common stock will begin trading on the NASDAQ on Monday, August 10, 2026. Wave does not anticipate any material impact to its employees or its day-to-day business as a result of the completion of the Redomiciliation.

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

Some of the statements included in this announcement may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, in particular, statements about our expectations regarding the change of the parent company of the group from a Singapore company to a Delaware corporation. These statements include, but are not limited to, statements that address our expected future business and statements about the Redomiciliation and other statements identified by words such as “will”, “expect”, “believe”, “anticipate”, “estimate”, “should”, “intend”, “plan”, “potential”, “predict”, “project”, “aim”, and similar words, phrases or expressions. These forward-looking statements are based on current expectations and beliefs of the management of Wave Life Sciences, as well as assumptions made by, and information currently available to, such management, current market trends and market conditions and involve risks and uncertainties, many of which are outside Wave Life Sciences’ and management’s control, and which may cause actual results to differ materially from those contained in forward looking statements. Accordingly, you should not place undue reliance on such statements.

Particular uncertainties that could materially affect future results include risks associated with the Redomiciliation; our ability to realize the expected benefits from the Redomiciliation; the occurrence of difficulties or material timing delays in connection with the Redomiciliation, including any unanticipated costs in connection therewith; any delays, challenges and expenses associated with receiving governmental and regulatory approvals; changes in tax laws, tax treaties or tax regulations or the interpretation or enforcement thereof by the tax authorities in Singapore, the United States and other jurisdictions following the Redomiciliation; our critical accounting policies; the ability of our preclinical studies to produce data sufficient to support the filing of global clinical trial applications and the timing thereof; our ability to continue to build and maintain the company infrastructure and personnel needed to achieve our goals; the clinical results and timing of our programs, which may not support further development of our product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; our effectiveness in managing current and future clinical trials and regulatory processes; the success of our platform in identifying viable candidates; the continued development and acceptance of nucleic acid therapeutics as a class of drugs; our ability to demonstrate the therapeutic benefits of our stereopure candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our ability to obtain, maintain and protect intellectual property; our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; our ability to fund our operations and to raise additional capital as needed; competition from others developing therapies for similar uses; and any impacts on our business as a result of or related to any local and global health epidemics, geopolitical conflicts, global economic uncertainty, the impact of tariffs and changes in economic policies, volatility in inflation, volatility in interest rates or market disruptions on our business.

The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are set forth in our definitive proxy statement filed on May 7, 2026 and our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the other documents that we file with the SEC, including under the heading “Risk Factors” in our most recent Annual Report on Form 10-K. You may obtain copies of these documents as described under the heading “Additional Information and Where to Find It.”

Our filings with the Securities and Exchange Commission (“SEC”), which you may obtain without charge at the SEC’s website at http://www.sec.gov, discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no intent or obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investors:

James Salierno
Director, Investor Relations
+1 617-949-4043
[email protected]

Media:

Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
[email protected]

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave's management team are scheduled to participate in two upcoming investor conferences in August.

Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript

Dosing underway in  Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also inform WVE-007's potential in MASH, type 2 diabetes, and other cardiometabolic diseases

Wave Life Sciences (WVE - Free Report) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.

Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.

As such, the Zacks rating upgrade for Wave Life Sciences is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.

For Wave Life Sciences, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for Wave Life SciencesThis biopharmaceutical company is expected to earn -$1.10 per share for the fiscal year ending December 2026, which represents no year-over-year change.

Analysts have been steadily raising their estimates for Wave Life Sciences. Over the past three months, the Zacks Consensus Estimate for the company has increased 20.7%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of Wave Life Sciences to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Shares of Wave Life Sciences (WVE - Free Report) have gained 2.1% over the past four weeks to close the last trading session at $5.81, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $22.93 indicates a potential upside of 294.7%.

The average comprises 15 short-term price targets ranging from a low of $12.00 to a high of $43.00, with a standard deviation of $10.34. While the lowest estimate indicates an increase of 106.5% from the current price level, the most optimistic estimate points to a 640.1% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.

However, an impressive consensus price target is not the only factor that indicates a potential upside in WVE. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.

Price, Consensus and EPS Surprise

Here's What You Should Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.

While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?

They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.

However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.

That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.

Why WVE Could Witness a Solid UpsideThere has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 4.6%, as one estimate has moved higher compared to no negative revision.

Moreover, WVE currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Therefore, while the consensus price target may not be a reliable indicator of how much WVE could gain, the direction of price movement it implies does appear to be a good guide.

Wave Life Sciences (WVE - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.

The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.

Therefore, the Zacks rating upgrade for Wave Life Sciences basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Wave Life Sciences imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.

Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for Wave Life SciencesThis biopharmaceutical company is expected to earn -$1.16 per share for the fiscal year ending December 2026, which represents no year-over-year change.

Analysts have been steadily raising their estimates for Wave Life Sciences. Over the past three months, the Zacks Consensus Estimate for the company has increased 12.5%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of Wave Life Sciences to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) hit a new 52-week low on Thursday. The company traded as low as $5.11 and last traded at $5.2590, with a volume of 11044062 shares traded. The stock had previously closed at $12.30. Trending Headlines about WAVE Life Sciences Here are the key news stories

Stock NewsWall Street rallies on Iran de-escalation hopes: Major U.S. indexes posted their best day since May, led by Big Tech as Nvidia NVDA rose over 5%, while oil eased on signals the U.S. could soon wind down operations in Iran. Source: Yahoo Finance.Gas tops $4, squeezing gig drivers: With U.S. gasoline averaging $4.02/gal, rideshare and delivery workers say higher fuel costs are pressuring earnings despite limited platform incentives from Uber UBER , Lyft LYFT , DoorDash DASH and Instacart CART . Source: CNN Business.Oracle cuts thousands amid AI buildout: Oracle (ORCL) began laying off employees globally as it ramps data center spending for AI workloads and contends with investor concerns around debt and cash flow. Source: CNBC.Global stocks jump, oil dips below $100 intraday: Equities rallied worldwide and crude briefly fell under $100 as optimism grew for a near-term end to the Iran war; AI-linked names like Marvell MRVL and Nvidia (NVDA) outperformed. Source: AP News.Japan sentiment improves, risks linger: The BOJ’s Tankan showed large manufacturers’ optimism at a multi‑year high, though HSBC HSBC cautioned rising energy costs and supply risks from the Iran conflict could cloud the outlook. Source: CNBC.Nike guides lower despite Q3 beat: NIKE NKE topped estimates but warned sales will decline for the year, including an expected ~20% drop in China this quarter, citing tariffs and geopolitical volatility. Source: CNBC.Unilever to combine Foods with McCormick: Unilever LON:ULVR agreed to merge its Foods business with McCormick MKC , creating a ~$20B global flavors player and leaving Unilever a focused HPC company. Source: Unilever.SpaceX lines up 21 banks for mega IPO: SpaceX engaged lead bookrunners Morgan Stanley MS , Goldman Sachs GS , JPMorgan JPM , Bank of America BAC and Citigroup C ahead of a highly anticipated listing. Source: CNBC.April Fools’ promos brew coffee buzz: Krispy Kreme DNUT launched a limited Artemis II-themed doughnut while Dunkin’ offered 1,000,001 free coffees to rewards members via app code StillNotAJoke. Source: USA TODAY.Compromised Axios npm package hits devs: A supply‑chain attack inserted a RAT via malicious Axios versions on npm, prompting safeguards for projects hosted on GitHub, part of Microsoft MSFT . Source: Malwarebytes.Allbirds agrees to $39M asset sale: Allbirds BIRD will sell its assets and IP to American Exchange Group for $39M, a steep drop from its 2021 IPO, with proceeds to be distributed post‑closing. Source: Yahoo Finance.OpenAI closes $122B round ahead of IPO chatter: OpenAI’s raise included Amazon AMZN , Nvidia (NVDA), Microsoft (MSFT) and SoftBank TYO:9984 , valuing the firm at ~$852B and expanding retail access via bank channels. Source: CNBC.Anthropic code leak exposes Claude internals: Anthropic confirmed a packaging error leaked parts of Claude Code’s source; no customer data was exposed, as competitors like Alphabet GOOGL watch closely. Source: CNBC.Google flags faster quantum timelines for crypto risk: Alphabet (GOOGL) researchers detailed lower qubit thresholds for breaking elliptic-curve cryptography, urging post‑quantum migration to protect blockchain systems. Source: Google Research.Juries find Meta liable in teen harm cases: Meta Platforms META and YouTube owner Alphabet (GOOGL) face verdicts over alleged addictive design and safety failures, with appeals planned and broader litigation ahead. Source: CNN Business.Consumer mood sours on war, gas and markets: U.S. sentiment fell to 53.3 in March as higher fuel costs and volatility weighed, though Apollo Global Management APO notes spending indicators remain resilient. Source: CNN Business.Yields ease on peace hopes after shaky auctions: The 10‑year Treasury fell to ~4.275% as de‑escalation talk lifted risk assets; banks like JPMorgan Chase (JPM) track labor and ISM data for rate path clues. Source: CNBC.Texas bans retail smokable hemp; fees surge: New Texas rules bar in‑state sales of smokable hemp and sharply raise licenses, highlighting regulatory risk for the sector and peers like Tilray Brands TLRY . Source: The Texas Tribune.Euro area inflation jumps on energy spike: Eurozone CPI accelerated to 2.5% in March on oil and gas costs, complicating ECB policy amid pressure on households and energy majors such as Shell SHEL . Source: CNBC.Mercedes refreshes GLE/GLS and boosts U.S. output: Mercedes‑Benz Group ETR:MBG unveiled extensively updated 2027 GLE/GLS models and plans a $4B Alabama investment by 2030 to expand U.S. production. Source: Automotive News.Upcoming EarningsConagra Brands Inc CAG will report today. Analysts estimate EPS 0.40 and revenue 2,762.78 million.Lamb Weston Holdings Inc LW will report today. Analysts estimate EPS 0.57 and revenue 1,492.32 million.MSC Industrial Direct Co Inc MSM will report today. Analysts estimate EPS 0.81 and revenue 931.73 million.Cal-Maine Foods Inc CALM will report today. Analysts estimate EPS 0.82 and revenue 641.98 million.PVH Corp PVH will report today. Analysts estimate EPS 3.37 and revenue 2,436.56 million.Upcoming DividendsAir Products and Chemicals Inc APD goes ex-dividend today for $1.81 (yield 2.46%).Federal Realty Investment Trust FRT goes ex-dividend today for $1.13 (yield 4.20%).State Street Corp STT goes ex-dividend today for $0.84 (yield 2.53%).Ingredion Inc INGR goes ex-dividend today for $0.82 (yield 2.88%).Vanguard Extended Duration Treasury ETF EDV goes ex-dividend today for $0.76 (yield 4.90%).Notable Insider TransactionsMineralys Therapeutics Inc MLYS — Ra Capital Healthcare Fund Lp, a Director, reported buying 369,000 shares at $23.75 ($8.76M total) Mar 31.Cogent Biosciences Inc COGT — Fairmount Funds Management Llc, a Director, reported selling 7,000,000 shares at $34.66 ($242.62M total) Mar 31.Ingram Micro Holding Corp INGM — Platinum Equity, Llc, a 10% Owner, reported selling 1,348,314 shares at $21.36 ($28.80M total) Mar 31.Precigen Inc PGEN — Randal J Kirk, a Director, 10% Owner, reported selling 4,772,781 shares at $3.30 ($15.75M total) Mar 31.WAVE Life Sciences Ltd (WVE) — Ra Capital Healthcare Fund Lp, a Director, 10% Owner, reported buying 8,772,496 shares at $6.23 ($54.65M total) Mar 30.Stock RatingsShell (SHEL) was upgraded by Weiss Ratings from "hold (c+)" to "buy (b-)".Trending DiscussionsPraveen: The deleveraging the company has undergone is a huge achievement. Hopefully now more of the FCF can now be applied to stock buybacks.Praveen: I don't see any margin of safety at this time. It is all said and done a cyclical industrial parts supplier. Better to wait for the inevitable trough…Mark: Thanks for this, agree that AI should be a net benefit for ADBE. A solid buy under 250.Praveen: The ticker associated with this article is UFPI and not FRA:UFP.GuruFocus Stock AnalysisThe Replacement Economics Behind Kirby Corporation's Inland Marine Advantage by Juned AalamPalo Alto Networks: The Selloff Creates an Opportunity in the AI Era by Renato Neves, CFAHenry Schein: A Cash-Generating Healthcare Distributor Priced for Mediocrity by Bano HaseenaForward Air After the Merger: Dislocation or Structural Impairment? by Raphaël BernardViatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight by Vega NorthThis stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

April 15, 2026 16:01 ET  | Source: Wave Life Sciences USA, Inc.

CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that its board of directors has unanimously approved a plan to redomicile the parent company of the Wave Life Sciences group of companies from Singapore to the United States (the Redomiciliation).

Through Wave Life Sciences’ listing on Nasdaq, the majority of the company’s operations, its corporate headquarters, the majority of its operating assets, including its manufacturing and research and development facilities, along with the majority of its employees, management team and board of directors being in the United States, Wave already has a substantial U.S. presence. Having Wave’s parent company domiciled in the United States will streamline Wave’s organizational, statutory and regulatory structure, resulting in administrative efficiencies and reducing dual financial reporting, regulatory, legal and other compliance costs, among other benefits.

“We believe the United States is the best place for Wave to enhance shareholder value. With several of our investigational therapies showing tremendous potential to become first- and/or best-in-class treatments, now is the right time and becoming a Delaware corporation is the right strategic move for Wave in order to better align our parent company’s domicile with our operations and our people,” said Kyle Moran, Chief Financial Officer of Wave Life Sciences.

Subject to the receipt of necessary Wave shareholder and Singapore High Court approvals, pursuant to the Redomiciliation transaction, the ordinary shares of the existing Singapore parent company (Wave Life Sciences Ltd.) will be exchanged on a one-for-one basis for common stock in a newly-formed Delaware parent corporation (Wave Life Sciences, Inc.). Wave Life Sciences, Inc. will become the ultimate parent company of the Wave Life Sciences group of companies and will operate the business of the group in substantially the same manner as the company has done previously. Upon completion of the Redomiciliation, the shares of common stock of the new Delaware parent corporation (Wave Life Sciences, Inc.) will continue to trade on the Nasdaq Global Market under Wave’s existing trading symbol “WVE”. The company will remain subject to the reporting requirements of the U.S. Securities and Exchange Commission (SEC) and the applicable rules of Nasdaq. Wave will continue to report its consolidated financial results in U.S. dollars and under U.S. generally accepted accounting principles.

Wave is filing its preliminary proxy materials with the SEC today in preparation for a company shareholder meeting to approve the Redomiciliation. The Redomiciliation is subject to the approval of Wave’s shareholders and the Singapore High Court. Subject to receiving the requisite approvals, Wave expects the Redomiciliation to take effect in mid-2026. The Redomiciliation is expected to be tax-free to Wave’s U.S. shareholders.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements
Some of the statements included in this announcement may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, in particular, statements about our expectations regarding the change of the parent company of the group from a Singapore company to a Delaware corporation. These statements include, but are not limited to, statements that address our expected future business and statements about the Redomiciliation and other statements identified by words such as “will”, “expect”, “believe”, “anticipate”, “estimate”, “should”, “intend”, “plan”, “potential”, “predict”, “project”, “aim”, and similar words, phrases or expressions. These forward-looking statements are based on current expectations and beliefs of the management of Wave Life Sciences, as well as assumptions made by, and information currently available to, such management, current market trends and market conditions and involve risks and uncertainties, many of which are outside Wave Life Sciences’ and management’s control, and which may cause actual results to differ materially from those contained in forward looking statements. Accordingly, you should not place undue reliance on such statements.

Particular uncertainties that could materially affect future results include risks associated with the Redomiciliation, including our ability to obtain shareholder and Singapore High Court approvals and satisfy other closing conditions to the completion of the Redomiciliation within the expected timeframe or at all; our ability to realize the expected benefits from the Redomiciliation; the occurrence of difficulties or material timing delays in connection with the Redomiciliation, including any unanticipated costs in connection therewith; any delays, challenges and expenses associated with receiving governmental and regulatory approvals; changes in tax laws, tax treaties or tax regulations or the interpretation or enforcement thereof by the tax authorities in Singapore, the United States and other jurisdictions following the Redomiciliation; our critical accounting policies; the ability of our preclinical studies to produce data sufficient to support the filing of global clinical trial applications and the timing thereof; our ability to continue to build and maintain the company infrastructure and personnel needed to achieve our goals; the clinical results and timing of our programs, which may not support further development of our product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; our effectiveness in managing current and future clinical trials and regulatory processes; the success of our platform in identifying viable candidates; the continued development and acceptance of nucleic acid therapeutics as a class of drugs; our ability to demonstrate the therapeutic benefits of our stereopure candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our ability to obtain, maintain and protect intellectual property; our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; our ability to fund our operations and to raise additional capital as needed; competition from others developing therapies for similar uses; and any impacts on our business as a result of or related to any local and global health epidemics, geopolitical conflicts, global economic uncertainty, the impact of tariffs and changes in economic policies, volatility in inflation, volatility in interest rates or market disruptions on our business.

The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the other documents that we file with the SEC, including under the heading “Risk Factors” in our most recent Annual Report on Form 10-K. You may obtain copies of these documents as described under the heading “Additional Information and Where to Find It.”

Additional Information and Where to Find It
In connection with the Redomiciliation, Wave Life Sciences expects to file with the SEC a proxy statement and other relevant documents. The definitive proxy statement will be mailed or otherwise disseminated to Wave Life Sciences’ shareholders and will contain important information about the Redomiciliation. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT WAVE LIFE SCIENCES LTD., WAVE LIFE SCIENCES, INC. AND THE REDOMICILIATION. Investors may obtain copies of the definitive proxy statement (when available), as well as other filings containing information about Wave Life Sciences, free of charge, at the SEC’s Internet website (http://www.sec.gov). Copies of these documents may also be obtained free of charge from Wave Life Sciences’ website at www.wavelifesciences.com.

Participants in Solicitation
Wave Life Sciences and certain of its executive officers and directors may be deemed to be participants in the solicitation of proxies from the shareholders of Wave Life Sciences in connection with the Redomiciliation. Information about the directors and executive officers of Wave Life Sciences, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in Wave Life Sciences’ proxy statement for its 2025 Annual Meeting of Shareholders, which was filed with the SEC on June 23, 2025. To the extent holdings of Wave Life Sciences ordinary shares by the directors and executive officers of Wave Life Sciences have changed from the amounts of Wave Life Sciences ordinary shares held by such persons as reflected therein, such changes have been or will be reflected on Initial Statements of Beneficial Ownership of Securities on Form 3, Statements of Changes in Beneficial Ownership on Form 4 or Annual Statements of Changes in Beneficial Ownership of Securities on Form 5, in each case filed or to be filed with the SEC, as applicable. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the definitive proxy statement when it is filed with the SEC and other relevant materials to be filed with the SEC regarding the Redomiciliation when such materials become available. You may obtain free copies of these documents as described in the preceding paragraph.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
[email protected]

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
[email protected]

April 22, 2026 08:30 ET  | Source: Wave Life Sciences USA, Inc.

CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, April 28, 2026, to review the company’s first quarter 2026 financial results and provide business updates.

The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.

Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here.

Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
[email protected]

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
[email protected]

Wave Life Sciences (WVE - Free Report) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +61.31%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.28 per share when it actually produced a loss of $0.3, delivering a surprise of -7.14%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Wave Life Sciences, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $38.25 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 256.61%. This compares to year-ago revenues of $9.18 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Wave Life Sciences shares have lost about 59.2% since the beginning of the year versus the S&P 500's gain of 4.8%.

What's Next for Wave Life Sciences?While Wave Life Sciences has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Wave Life Sciences was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.37 on $8.45 million in revenues for the coming quarter and -$1.39 on $37.78 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Kymera Therapeutics, Inc. (KYMR - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on April 30.

This company is expected to post quarterly loss of $0.89 per share in its upcoming report, which represents a year-over-year change of -8.5%. The consensus EPS estimate for the quarter has been revised 1.4% lower over the last 30 days to the current level.

Kymera Therapeutics, Inc.'s revenues are expected to be $11.02 million, down 50.1% from the year-ago quarter.

Data reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing

The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.

, /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation (A1F), today announced Wave Life Sciences as an inaugural industry sponsor. The support further strengthens efforts to accelerate routine targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in people impacted by liver and/or lung disease, consistent with clinical practice guidelines.

Wave Life Science AlphaDetect is dedicated to identifying everyone at risk for this progressive, irreversible genetic condition by elevating awareness and removing barriers to detection. The organization will provide free genetic testing for Alpha-1 in their proprietary laboratory, at no cost to insurance or patients. In addition, they provide support from a committed engagement team for healthcare providers. These efforts will increase the availability of Alpha-1 detection tools and support at the practice level while also partnering with healthcare providers to strategically advance protocols and technologies across healthcare systems.

"We know from conversations with the Alpha-1 community that AATD (Alpha-1 Antitrypsin Deficiency) is highly underdiagnosed and often misdiagnosed. We're proud to support AlphaDetect as an inaugural sponsor and especially excited about this centralized lab for Alpha-1 testing and detection, supported by a team dedicated to the Alpha-1 community," said Christopher Wright, MD, PhD, Chief Medical Officer at Wave Life Sciences. "In addition to genetic testing, AlphaDetect is part of a broader effort to connect people living with Alpha-1 to care, resources, and ongoing research that may potentially have a significant impact on their quality of life and the progression of their disease."

"Alpha-1 is a progressive, genetic lung and liver condition where delays in detection may have real, irreversible consequences," said Julie Murray, CEO of AlphaDetect. "The ability to scale proven approaches to identifying at-risk patients, quickly and systematically, can inform timely decisions for those impacted. The support and commitment from Wave Life Sciences are important and appreciated as we continue to advance Alpha-1 detection."

Alpha-1 remains significantly underdiagnosed, with more than 90% of affected individuals estimated to be unidentified. It is also the leading known genetic risk factor for COPD and is associated with liver disease in both children and adults. Importantly, detection also provides a point of entry into the Alpha-1 community, opening the door to the comprehensive information, support, and resources needed for the journey ahead.

"This support builds on Wave Life Science's focus on novel approaches to support the Alpha-1 community and represents an important step forward in how we advance detection," said Scott Santarella, CEO of the Alpha-1 Foundation. "By expanding these efforts through AlphaDetect, we can identify more individuals earlier and deliver on A1F's mission of improving their lives."

The latest clinical guidelines recommend testing for Alpha-1 in all individuals with COPD, treatment-resistant asthma, or unexplained liver disease. Yet real-world results fall far short of this. AlphaDetect is committed to closing the gap. Wave Life Science's sponsorship and commitment will help AlphaDetect scale efforts to enhance provider education, broaden detection strategies, and work across the Alpha-1 community to identify individuals with Alpha-1.

About AlphaDetect 

AlphaDetect, founded in 2025, accelerates detection to uncover everyone genetically at risk for Alpha-1. Located in Durham, NC, AlphaDetect will operate as a limited liability company and a non-profit subsidiary of Alpha-1 Foundation, holding tax-exempt status under Section 501(c)3 of the Internal Revenue Code. 

For more information, visit https://alpha1.org/alphadetect/

Contact: Cindy Machles

917-453-9760

Email: [email protected]

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington's disease, as well as several preclinical programs utilizing the company's versatile RNA medicines platform. Driven by the calling to "Reimagine Possible," Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

For more information, visit www.wavelifesciences.com

Contact: Katie Sullivan

Senior Director, Corporate Communications

617-949-2936

[email protected]

About the Alpha-1 Foundation

The Alpha-1 Foundation, founded in 1995, is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by the condition worldwide. A1F has invested over $100 million to support Alpha-1 research and programs at 130 institutions in North America, Europe, the Middle East and Australia.

For more information, visit alpha1.org

Contact: Jeanne Kushner

Senior Director of Communications & Policy

877-228-7321

[email protected]

SOURCE Alpha-1 Foundation

SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Wave Life Sciences Ltd. (NASDAQ: WVE) or certain of its executive officers violated federal securities laws. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

What if I purchased Wave Life Sciences securities?
If you purchased Wave Life Sciences securities and suffered losses on your investment, join our investigation now: Click Here to Join the Investigation.

Or for more information, contact Jim Baker at [email protected] or (619) 814-4471.

There is no cost or obligation to you.

Background of the Investigation
On March 26, 2026, Wave Life Sciences announced positive interim Phase 1 data from INLIGHT, its clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA for people living with overweight or obesity.

Wave reported that, at six-month follow-up, a single 240 mg dose of WVE-007 produced placebo-adjusted reductions in visceral fat of 14.3%, total fat of 5.3%, waist circumference of 3.3%, and body weight of 0.9%, while lean mass increased 2.4%. The Company also reported that, in the 400 mg cohort, three-month data showed placebo-adjusted reductions in visceral fat of 5.0% and total fat of 0.7%, with lean mass preservation.

Following this news, Wave’s stock declined sharply, damaging investors.

In light of these disclosures, Johnson Fistel is investigating whether Wave Life Sciences complied with state and federal laws, including the federal securities laws. If you suffered losses, or are a long-term holder of Wave Life Sciences stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Top Law Firm – Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder class actions and derivative lawsuits. Johnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. In 2024, the firm recovered approximately $90,725,000 for investors.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | [email protected] | [email protected]

June 01, 2026 08:30 ET  | Source: Wave Life Sciences USA, Inc.

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in June.

2026 Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Details: Paul Bolno, MD, MBA, President and CEO, will participate in an analyst-led fireside chat at 10:30 a.m. ET

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Monday, June 8, 2026
Details: Dr. Bolno will participate in an analyst-led fireside chat at 8:00 a.m. ET

Live webcasts of the presentations can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Replays of these presentations will be archived and available on the site for a limited time following the event.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
[email protected]

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
[email protected]